Health-Biotech JISHI

Fujian Hanlian Jishi Biotechnology (operating as H&B JISHI) is a clinical-stage Chinese biotechnology company specializing in the development of off-the-shelf, innovative cellular medicines and regenerative therapies. As a core drug development arm of Han's United Group, the company leverages its proprietary perinatal mesenchymal stem cell (MSC) platforms to address severe and life-threatening diseases. Its clinical pipeline, largely driven by its holding subsidiary Tianjin Angsai Cell Gene Engineering (the legal entity of the National Engineering Research Center for Cell Products), features advanced candidates such as umbilical cord-derived MSCs (UC-MSCs) in Phase II/III trials for steroid-refractory acute graft-versus-host disease (SR-aGVHD) and acute-on-chronic liver failure (ACLF). Additionally, H&B JISHI is advancing placenta-derived MSC hydrogels for diabetic foot ulcers and radiation skin injuries, alongside VCAM-1+ MSCs for critical limb ischemia.